AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32687899 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 9
Study 32687899 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA)
Number of subjects: 9
Study 32687899 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (2 mA)
Number of subjects: 9
Study 32687899 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1 mA) over right PFC
Number of subjects: 9
Study 32687899 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (1 mA) over right PFC
Number of subjects: 9
Study 32687899 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA) over right PFC
Number of subjects: 9
Study 32687899 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (2 mA) over right PFC
Number of subjects: 9
Study 32687977 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic resection
Number of subjects: 693
Study 32687977 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection
Number of subjects: 693
Study 32687977 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesion size (per mm increase)
Number of subjects: 693
Study 32687977 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal location
Number of subjects: 693
Study 32687977 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model based on lesion size and rectal location
Number of subjects: 693
Study 32687977 — intervention group
Group type: EXPERIMENTAL
Intervention: NNT for nonrectal SMIC smaller than 4 cm
Number of subjects: 693
Study 32687977 — intervention group
Group type: EXPERIMENTAL
Intervention: NNT for rectal SMIC of 4 cm or more
Number of subjects: 693
Study 32689822 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse LV remodeling (≥12% decrease in LVESV)
Number of subjects: 285
Study 32689822 — intervention group
Group type: EXPERIMENTAL
Intervention: No LV remodeling (changes in LVEDV and LVESV <12%)
Number of subjects: 285
Study 32689822 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse LV remodeling with compensation (≥12% increase in LVEDV only)
Number of subjects: 285
Study 32689822 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse LV remodeling (≥12% increase in both LVESV and LVEDV)
Number of subjects: 285
Study 32689933 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal characteristics (BMI, glucose tolerance, mode of delivery, ethnicity)
Number of subjects: 113
Study 32689965 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-fallers (NFs)
Number of subjects: 83
Study 32689965 — intervention group
Group type: COMPARATOR
Intervention: One-time fallers (OFs)
Number of subjects: 83
Study 32689965 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent-fallers (RFs)
Number of subjects: 83
Study 32689979 — intervention group
Group type: EXPERIMENTAL
Intervention: RefluxStop™ device
Number of subjects: 50
Study 32689982 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding Stroke web-based decision support tool
Number of subjects: 0
Study 32690030 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia patients
Number of subjects: 23
Study 32690030 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing butyrate producing bacteria and targeting malnutrition
Number of subjects: 23
Study 32690156 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified fat breast milk (MFBM) - Target Fortification (n=8)
Number of subjects: 24
Study 32690156 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified fat breast milk (MFBM) - Higher Initial Concentration (n=8)
Number of subjects: 24
Study 32690156 — intervention group
Group type: COMPARATOR
Intervention: High medium triglyceride (MCT) formula (n=8)
Number of subjects: 24
Study 32690157 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training three times a week for 12 weeks
Number of subjects: 17
Study 32690157 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training
Number of subjects: 17
Study 32690246 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate reduction intervention
Number of subjects: 45
Study 32690505 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal suicide risk screening using smartphone technology
Number of subjects: 137927
Study 32690505 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of mental health outcomes (depression, anxiety, alcohol and substance use disorders)
Number of subjects: 137927
Study 32690535 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servoventilation (ASV)
Number of subjects: 503
Study 32690535 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients who refused ASV or stopped treatment early)
Number of subjects: 503
Study 32690678 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural-neuroimaging datasets
Number of subjects: 0
Study 32690727 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal radiography (AR)
Number of subjects: 200
Study 32690727 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal ultrasound (AUS) as an add-on test with AR
Number of subjects: 200
Study 32690727 — intervention group
Group type: EXPERIMENTAL
Intervention: AR and AUS
Number of subjects: 200
Study 32690731 — intervention group
Group type: EXPERIMENTAL
Intervention: Serological HPA-1a typing and luminex-based multiplex assay for detection of anti-HPA-1a antibodies.
Number of subjects: 0
Study 32690731 — intervention group
Group type: COMPARATOR
Intervention: HPA-1a immunised pregnancies with and without signs of bleeding.
Number of subjects: 0
Study 32690735 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotherapy optimisation strategy
Number of subjects: 0
Study 32690735 — intervention group
Group type: COMPARATOR
Intervention: Classic permissive strategy of antibiotic prophylaxis and treatment
Number of subjects: 0
Study 32690786 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-responsive neurostimulation
Number of subjects: 230
Study 32690797 — intervention group
Group type: EXPERIMENTAL
Intervention: bimagrumab 10 mg/kg IV every 4 weeks up to 2 years (104 weeks)
Number of subjects: 10
Study 32690798 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous EEG monitoring (CEEG)
Number of subjects: 719
Study 32691048 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime sleep duration (increased)
Number of subjects: 0
Study 32691048 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime sleep duration (baseline increase)
Number of subjects: 0
Study 32691048 — intervention group
Group type: COMPARATOR
Intervention: Nighttime sleep duration (no change or decrease)
Number of subjects: 0
Study 32691060 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoantigen vaccines
Number of subjects: 0
Study 32691060 — intervention group
Group type: EXPERIMENTAL
Intervention: Checkpoint blockade
Number of subjects: 0
Study 32691060 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of neoantigen vaccines and checkpoint blockade
Number of subjects: 0
Study 32691060 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 32691232 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic single flap tympanoplasty
Number of subjects: 104
Study 32691232 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic double flap tympanoplasty
Number of subjects: 104
Study 32691242 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarucizumab (2.5 + 2.5 g, intravenous) administered 2 hours after the last administration of dabigatran etexilate (220 mg b.i.d., oral)
Number of subjects: 12
Study 32691242 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran etexilate (220 mg b.i.d., oral) alone
Number of subjects: 12
Study 32691879 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience training
Number of subjects: 1315
Study 32692109 — intervention group
Group type: EXPERIMENTAL
Intervention: Epi-PrEP (short-term, fixed-interval episodic PrEP)
Number of subjects: 54
Study 32692282 — intervention group
Group type: EXPERIMENTAL
Intervention: Effortful control
Number of subjects: 0
Study 32692282 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity
Number of subjects: 0
Study 32692301 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol-enhanced MR angiography
Number of subjects: 59
Study 32692301 — intervention group
Group type: COMPARATOR
Intervention: Duplex US
Number of subjects: 59
Study 32692345 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-Processed Foods (UPFs) consumption by vegetarians
Number of subjects: 21212
Study 32692345 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional quality of diets measured by healthy plant-based diet indices (PDI)
Number of subjects: 21212
Study 32692345 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at vegetarian diet initiation
Number of subjects: 21212
Study 32692345 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of vegetarian diet
Number of subjects: 21212
Study 32692356 — intervention group
Group type: EXPERIMENTAL
Intervention: High social support (+1 SD)
Number of subjects: 143
Study 32692356 — intervention group
Group type: EXPERIMENTAL
Intervention: Low social support (-1 SD)
Number of subjects: 143
Study 32692356 — intervention group
Group type: EXPERIMENTAL
Intervention: High social support
Number of subjects: 143
Study 32692356 — intervention group
Group type: EXPERIMENTAL
Intervention: Low social support
Number of subjects: 143
Study 32692367 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 g GOS
Number of subjects: 46
Study 32692367 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 g GOS
Number of subjects: 46
Study 32692367 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g GOS
Number of subjects: 46
Study 32692367 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 g GOS with 93 mg AA
Number of subjects: 46
Study 32692450 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg daily for days 1-21 of 28-day cycles)
Number of subjects: 21
Study 32692715 — intervention group
Group type: EXPERIMENTAL
Intervention: cTOI/pTOI-ratio
Number of subjects: 87
Study 32692715 — intervention group
Group type: EXPERIMENTAL
Intervention: cTOI
Number of subjects: 87
Study 32692715 — intervention group
Group type: EXPERIMENTAL
Intervention: pTOI
Number of subjects: 87
Study 32692715 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 87
Study 32692715 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial blood pressure
Number of subjects: 87
Study 32692715 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial oxygen saturation
Number of subjects: 87
Study 32692715 — intervention group
Group type: EXPERIMENTAL
Intervention: Body temperature
Number of subjects: 87
Study 32692850 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg IV every 3 weeks
Number of subjects: 12
Study 32692850 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 12
Study 32693406 — intervention group
Group type: EXPERIMENTAL
Intervention: Undetectable measurable residual disease (MRD) in patients with standard- or high-risk CAs
Number of subjects: 390
Study 32693406 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent MRD in patients with standard-risk CAs
Number of subjects: 390
Study 32693406 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent MRD in patients with high-risk CAs
Number of subjects: 390
Study 32693411 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided through-the-needle biopsy (TTNB)
Number of subjects: 101
Study 32693411 — intervention group
Group type: COMPARATOR
Intervention: Fine needle aspiration (FNA) cytology
Number of subjects: 101
Study 32693812 — intervention group
Group type: EXPERIMENTAL
Intervention: Collateral donor artery post-PCI
Number of subjects: 31
Study 32693812 — intervention group
Group type: COMPARATOR
Intervention: Collateral donor artery pre-PCI
Number of subjects: 31
Study 32693812 — intervention group
Group type: EXPERIMENTAL
Intervention: Recanalized coronary artery post-PCI
Number of subjects: 31
Study 32694147 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic prediction model based on symptoms only
Number of subjects: 193
Study 32694147 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding blood markers
Number of subjects: 193
Study 32694147 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding stool markers
Number of subjects: 193
Study 32694147 — intervention group
Group type: EXPERIMENTAL
Intervention: Combining symptoms with blood and stool markers
Number of subjects: 193
Study 32694147 — intervention group
Group type: EXPERIMENTAL
Intervention: Triaging with symptoms, blood markers, and calprotectin
Number of subjects: 193
Study 32694158 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 300 MBq of (4S)-4-(3-[
Number of subjects: 20
Study 32694159 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Number of subjects: 0
Study 32694182 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygenation factor
Number of subjects: 150
Study 32694182 — intervention group
Group type: COMPARATOR
Intervention: Oxygenation ratio
Number of subjects: 150
Study 32694398 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorimetric blood loss measurement
Number of subjects: 53
Study 32694398 — intervention group
Group type: EXPERIMENTAL
Intervention: Gravimetric technique
Number of subjects: 53
Study 32694398 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual technique
Number of subjects: 53
Study 32694787 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence decision support system for the management of T1D
Number of subjects: 0
Study 32694834 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA methylation (DNAme)
Number of subjects: 499
Study 32694834 — intervention group
Group type: EXPERIMENTAL
Intervention: mean-DCCT HbA1c
Number of subjects: 499
Study 32694857 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 277
Study 32694857 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent wheeze
Number of subjects: 277
Study 32694857 — intervention group
Group type: EXPERIMENTAL
Intervention: Other children in the household <5 years old
Number of subjects: 277
Study 32694949 — intervention group
Group type: COMPARATOR
Intervention: Apex group (Group A)
Number of subjects: 106
Study 32694949 — intervention group
Group type: EXPERIMENTAL
Intervention: True septum group
Number of subjects: 106
Study 32694949 — intervention group
Group type: EXPERIMENTAL
Intervention: False septum group
Number of subjects: 106
Study 32694949 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate model
Number of subjects: 106
Study 32695433 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcroze eurhythmics program
Number of subjects: 18
Study 32695433 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple home exercise program (SHEP)
Number of subjects: 18
Study 32695433 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control group
Number of subjects: 18
Study 32695435 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention for managing urinary incontinence in athletic women.
Number of subjects: 0
Study 32695435 — intervention group
Group type: COMPARATOR
Intervention: Semi-structured interviews with health care professionals.
Number of subjects: 0
Study 32695435 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-structured interviews with participants from phase 2.
Number of subjects: 0
Study 32695435 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a smartphone 'app' for adherence and monitoring of home exercises.
Number of subjects: 0
Study 32695435 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploration of the impact of UI on life and sport.
Number of subjects: 0
Study 32695577 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean medicine treatments for LBP
Number of subjects: 150
Study 32695923 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme for blood management (non-drug intervention) in group A
Number of subjects: 900
Study 32695923 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic correction of perioperative iron, vitamin deficiencies, and anaemia (drug intervention) in group B
Number of subjects: 900
Study 32695954 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation program (twice a week for 3 months)
Number of subjects: 0
Study 32695954 — intervention group
Group type: COMPARATOR
Intervention: Usual standard postoperative rehabilitation
Number of subjects: 0
Study 32695957 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% watermelon juice
Number of subjects: 0
Study 32695957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32695960 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (RIS)
Number of subjects: 439
Study 32695960 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (OLZ)
Number of subjects: 439
Study 32695960 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (RIS) or Olanzapine (OLZ)
Number of subjects: 439
Study 32696267 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash Glucose Monitoring (FGM) system
Number of subjects: 74
Study 32696267 — intervention group
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre™
Number of subjects: 74
Study 32696266 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13
Number of subjects: 248
Study 32696266 — intervention group
Group type: COMPARATOR
Intervention: Reference Infliximab
Number of subjects: 248
Study 32696319 — intervention group
Group type: EXPERIMENTAL
Intervention: TTC-352 (180 mg twice a day)
Number of subjects: 15
Study 32696319 — intervention group
Group type: EXPERIMENTAL
Intervention: TTC-352
Number of subjects: 15
Study 32696441 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir 600 mg q24h
Number of subjects: 127
Study 32696441 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir 400 mg q24h
Number of subjects: 127
Study 32696441 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir 800 mg q24h for 5 days followed by 2 days of treatment interruption
Number of subjects: 127
Study 32696441 — intervention group
Group type: COMPARATOR
Intervention: Current treatment guidelines (darunavir 800 mg q24h or 600 mg q12h)
Number of subjects: 127
Study 32696449 — intervention group
Group type: EXPERIMENTAL
Intervention: NOACs
Number of subjects: 279
Study 32696449 — intervention group
Group type: COMPARATOR
Intervention: VKAs
Number of subjects: 279
Study 32696663 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic management focusing on stroke/systemic embolism prevention, uptake of new oral anticoagulants
Number of subjects: 57149
Study 32696663 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk prediction tool and innovative observational studies
Number of subjects: 57149
Study 32696697 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched marine oil supplement (3 escalating doses, 5-day oral administration)
Number of subjects: 20
Study 32697509 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive leg raising test
Number of subjects: 50
Study 32697509 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in central venous pressure greater than or equal to 4 mm Hg during passive leg raising
Number of subjects: 50
Study 32697513 — intervention group
Group type: EXPERIMENTAL
Intervention: Venoarterial extracorporeal membrane oxygenation implantation
Number of subjects: 257
Study 32697513 — intervention group
Group type: EXPERIMENTAL
Intervention: Late implantation of venoarterial extracorporeal membrane oxygenation
Number of subjects: 257
Study 32697513 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative left ventricular ejection fraction
Number of subjects: 257
Study 32697513 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative plasma transfusion
Number of subjects: 257
Study 32697513 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased bilirubinemia level
Number of subjects: 257
Study 32697513 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased creatinine levels on the day of implantation
Number of subjects: 257
Study 32697965 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (nCRT) followed by total mesorectal excision (TME) in high-risk patients
Number of subjects: 1093
Study 32697965 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (nCRT) followed by TME in clinical stages II and III patients
Number of subjects: 1093
Study 32697965 — intervention group
Group type: COMPARATOR
Intervention: Primary surgery in clinical stages II and III patients
Number of subjects: 1093
Study 32697965 — intervention group
Group type: COMPARATOR
Intervention: Primary surgery in all patients
Number of subjects: 1093
Study 32697965 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (nCRT) in all patients
Number of subjects: 1093
Study 32698195 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib 160 mg orally twice daily (n = 50)
Number of subjects: 77
Study 32698195 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib 320 mg orally once daily (n = 23)
Number of subjects: 77
Study 32698195 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 77
Study 32698532 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaya Mosaic Virus adjuvant (30 to 240 µg) combined with trivalent influenza vaccine
Number of subjects: 0
Study 32698532 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32698642 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of cefazolin
Number of subjects: 242179
Study 32698642 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of cefuroxime
Number of subjects: 242179
Study 32698642 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of cefazolin
Number of subjects: 242179
Study 32698642 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of cefazolin (knee)
Number of subjects: 242179
Study 32698642 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of cefuroxime (knee)
Number of subjects: 242179
Study 32698642 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of cefazolin (knee)
Number of subjects: 242179
Study 32698775 — intervention group
Group type: EXPERIMENTAL
Intervention: One lung ventilation (OLV)
Number of subjects: 302
Study 32698775 — intervention group
Group type: COMPARATOR
Intervention: Two lung ventilation (TLV)
Number of subjects: 302
Study 32698775 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic approach
Number of subjects: 302
Study 32698775 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 302
Study 32698775 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive ventilation during general anesthesia
Number of subjects: 302